. Importantly, dissemination has already occurred in many patients at the time of diagnosis 1 . Adjuvant treatments are thought to prevent the development of local recurrences or metastasis by targeting residual disease. However, although some patients benefit temporarily from hormonal or targeted therapies 2 , adjuvant treatments are not always effective. Why is this? The answer may lie in the fact that the biology of residual disseminated disease seems to be highly divergent from that of the primary tumour and/or overt metastasis 3 . This divergence includes the ability of the disseminated disease to remain clinically asymptomatic 3, 4 because disseminated tumour cells (DTCs) can enter dormancy and become refractory to targeted or conventional therapies 1, 2, 4 FIG. 1) . Unfortunately, our knowledge of the biology of dormant disseminated disease is cripplingly limited. Understanding dormancy is important because dormant cells may be the source of tumour recurrence. For example, ~62% of all deaths from breast cancer occur after the 5-year survival mark 1 , suggesting that dormant DTCs may cause recurrence and that targeting dormant DTCs may be of great benefit to many patients.
The heterogeneity of primary and secondary tumours is also expected to exist in residual dormant cancer (FIG. 1) . Although clinical dormancy is well documented 1, 5 , this clinical definition is of little use without a mechanistic understanding. Tumour dormancy was originally defined by Willis in the late 1940s and then redefined by Hadfield in the early 1950s as a temporary mitotic arrest 6 and a growth arrest 1
. Dormancy was later divided into three categories 4 : cellular dormancy, where intrinsic and/or extrinsic mechanisms drive solitary or small groups of DTCs to enter quiescence
; angiogenic dormancy, where the tumour mass is kept constant by a balance between dividing cells and cells that die due to poor vascularization; and immune-mediated dormancy, where the immune system keeps a proliferating tumour mass constant via a persistent cytotoxic activity. These categories are not static, as processes that affect single cells may share underlying mechanisms with processes that affect the tumour mass. Clinical evidence supports the idea that DTCs are non-proliferative, as determined by the lack of proliferation markers when DTCs are profiled at the single-cell level [7] [8] [9] , arguing that they enter cellular dormancy. In particular, quiescence may be more fitting than senescence as a functional definition for cellular dormancy (BOX 2) . Similar to senescence, quiescence is a stable, non-proliferative cellular state, but in contrast to senescence, quiescence is reversible.
Current therapies target proliferating tumour cells with varying success. Thus, the idea of 'awakening' dormant cells in order to kill them 10 in the absence of effective and specific cytotoxic therapies could worsen patient outcome (BOX 3) . However, and perhaps counterintuitively, if DTCs could be kept dormant or could be eradicated while dormant, this would constitute a novel strategy to prevent metastasis 11 . Achieving such a clinical goal requires the answers to several important questions, Abstract | Metastases arise from residual disseminated tumour cells (DTCs). This can happen years after primary tumour treatment because residual tumour cells can enter dormancy and evade therapies. As the biology of minimal residual disease seems to diverge from that of proliferative lesions, understanding the underpinnings of this new cancer biology is key to prevent metastasis. Analysis of approximately 7 years of literature reveals a growing focus on tumour and normal stem cell quiescence, extracellular and stromal microenvironments, autophagy and epigenetics as mechanisms that dictate tumour cell dormancy. In this Review, we attempt to integrate this information and highlight both the weaknesses and the strengths in the field to provide a framework to understand and target this crucial step in cancer progression.
Dormant
A state of suspended animation or low activity of a cell or organism.
Niches
A term borrowed from ecology, it refers to a unique optimal tissue microenvironment with defined nurturing and positional cues in a given anatomical location that allows a cell or a group of cells to survive and function.
Tumour cell spheroids
Clusters of cells in a ball-like structure that can exist in suspension, for example, in the peritoneal fluid of patients with ovarian cancer. These spheroids commonly shed cells into the peritoneal cavity.
Omentum
A layer of tissue from the peritoneum that connects abdominal viscera and the stomach that is a protective and supporting cover.
Mesothelium
A mesoderm-derived epithelium that lines the body cavities.
which are explored in this Review. Here, we analyse data focusing on stress signalling and autophagy pathways linked to solitary tumour cell dormancy; microenvironments supportive of or restrictive for dormancy; and the role of stem cell, immune and vascular niches in the regulation of dormancy phenotypes. For information on the link between cancer stem cells, epithelial -mesenchymal transition (EMT) and cancer dormancy, please see recent reviews on these topics 12, 13 . Here, we integrate the literature published since we last reviewed the field 4 to provide avenues for answering important questions on the biology and relevance of tumour cell dormancy.
Coordination of quiescence and autophagy
Reduced PI3K-AKT signalling has been linked to dormancy-like phenotypes [14] [15] [16] [17] . In the presence of nutritional stress, cancer cells secrete factors that inhibit the PI3K pathway, resulting in quiescence and autophagy induction 14 . In tumour cell spheroids, loss of adhesion and nutrient deprivation promoted short-term growth arrest. This arrest was linked to epidermal growth factor receptor (EGFR)-Y1086 autophosphorylation, which inhibited AKT activation and cyclin D1 induction 15 . Although in vivo validation is still lacking, these findings might be clinically relevant. Balz et al. 16 , were able to obtain cell lines from human bone marrow-derived breast cancer DTCs, despite their lack of proliferation in that compartment. Although difficult, cell lines from DTCs dormant in vivo can be expanded in culture and they appear to still carry characteristics of the in vivo phenotype 18 . Similarly, cancer cell lines that grow easily in vitro can show dormant behaviour in vivo [19] [20] [21] . For example, Balz et al., found that these DTC-derived cell lines contained weak or undetectable AKT-S473 phosphorylation 16 . Although this does not affect in vitro proliferation where growth factors are in excess, constitutive reduction in the ATK signalling pathway may predispose these cells to entering quiescence in vivo. Although correlative, the non-proliferative status of bone marrow DTCs in the bone marrow of patients, as determined by the absence of proliferation markers such as Ki67 and PCNA 8 , together with the reduction of phosphorylated AKT in these cells, suggests that PI3K-AKT inhibition might be linked to DTC quiescence 14, 16 . Furthermore, in dormant head and neck squamous cell carcinoma (HNSCC) tumour cells the levels of AKT phosphorylation were reduced 17 . However, these quiescent tumour cells maintained mTOR activation independently of AKT by upregulating the small GTPase RHEB via the transcription factor ATF6α. Both RHEB and ATF6α promoted the survival of the dormant HNSCC cells by protecting them from apoptosis 17 . Thus, specific rewiring of pathways that coordinate metabolic homeostasis and survival during growth arrest might be a feature of dormant DTCs.
Tumour cells detached from the extracellular matrix (ECM) can survive by inhibiting AKT signalling and by inducing autophagy and an antioxidant response 22 . Floating tumour spheroids of ovarian cancer cell lines or spheroids isolated directly from patients' peritoneal fluid (ascites) were shown by one study to enter a G0/G1 arrest 23 . This arrest was due to AKT inhibition and increased p130 (also known as RBL2) and p27 (also known as KIP1) protein levels, which sequester RB and inhibit cyclin-dependent kinase 4 (CDK4) and/or CDK6 activity to induce G0/G1 arrest. If tumour cells re-adhered, AKT was activated and proliferation ensued 23 , with the cells escaping the G0/G1 growth arrest. Because ovarian cancer metastases are usually in the omentum and mesothelium 24 it is important to establish whether dormant DTCs persist in these anatomical sites or whether cellular dormancy is only a property of suspended cells in the peritoneum.
Autophagy might allow dormant DTCs to maintain metabolic fitness while inhibiting PI3K-AKT signalling, although reducing this signal may not always inhibit mTOR activation 17 . For instance, ARHI (also known as DIRAS3 and RHOI), a RAS homologue that is downregulated in 60-70% of ovarian cancers, was found to be upregulated along with p21 (a CDK inhibitor) in dormant ovarian tumours in mice 25 . ARHI inhibited PI3K-mTOR signalling and induced the expression of autophagyrelated gene 4 (ATG4) and LC3 (also known as ATG8), suggesting that it induces autophagy 25 . RNA interference (RNAi)-mediated downregulation of ARHI interrupted dormancy and tumours resumed growth in mice. Interestingly, inhibition of autophagy using chloroquine in tumours that had been rendered dormant by AHRI Box 1 | Early dissemination as a source of heterogeneity, dormant DTCs and pre-metastatic niches Dormancy of disseminated tumour cells (DTCs) may not be a process exclusive to metastatic cells that arise from established primary tumours. This is because pre-invasive lesions also contain epithelial cells that can undergo epithelialmesenchymal transition and disseminate; these cells are referred to as early DTCs. Such early DTCs can develop metastatic growth capacity that manifests after long periods of dormancy 1, 66 (FIG. 1) . Early dissemination, which has not been explored by many laboratories 65, 66, 141 , has important implications. First, by disseminating at early stages, DTCs that survive and eventually divide may evolve divergently from the primary tumour. This may generate metastases with different characteristics from those of the primary lesion and may explain the lack of success of treating metastasis with therapies designed exclusively on the basis of primary tumour characteristics. Second, the vast majority of early DTCs in mouse models seem to be dormant, and clinical evidence supports this hypothesis 65, 66 . This suggests that persistence in a dormant state even with interspersed division such as that observed in adult haematopoietic stem cells 119 Blocking survival signals during drug-induced dormancy is an attractive possibility 31 . Bortezomib (a proteasome inhibitor) induces quiescence in surviving multiple myeloma cells 31 , which have dephosphorylated eIF2α (eukaryotic translation initiation factor 2α) and reduced endoplasmic reticulum (ER) stress-related apop totic gene induction
. Importantly, salubrinal, a GADD34-PP1c (eIF2α phosphatase) inhibitor, not only potentiated bortezomib cell killing, but also induced apoptosis in the quiescent tumour cells that survived bortezomib 31 . Similarly, in non-small-cell lung cancer (NSCLC) xenografts treated with an EGFR inhibitor (erlotinib), tumour cells entered a quiescence-like state, and cells that survived this treatment eventually grew after a prolonged arrest (BOX 3) but were eliminated when erlotinib was combined with the BH3-mimetic ABT-737 (a BCL-2 and BCL-X L inhibitor) 32 . The erlotinib-surviving fractions displayed increased levels of phosphorylated signal transducer and activator of transcription 3 (STAT3), a cancer cell survival regulator 32 . It is possible that microenvironmental or drug-induced stress conditions induce survival in quiescent tumour cells via autophagy or other stress-related proteins (for example, increased BCL-2 expression or decreased proteinase-activated receptor 4 (PAR4) 33 expression).
Quiescence and stress tolerance signalling Although reduced mitogenic signalling can trigger quiescence, specific kinases such as dual specificity tyrosinephosphorylation-regulated kinase 1B (DYRK1B) can actively induce this state 34, 35 . In pancreatic and ovarian cancer cells DYRK1B blocks the G0/G1/S transition machinery proteins, including cyclin D1, CDK4 and p27 (REFS 34, (36) (37) (38) . A related kinase, DYRK1A, can also induce quiescence or RAS-induced senescence via the activation of the DREAM (DP, RB, E2F and MuvB) complex that induces G0 arrest during quiescence by repressing cell cycle genes 34, 39 . Interestingly, DYRK1B also coordinates survival via an antioxidant response, and inhibition of this kinase, through unknown mechanisms, seems to specifically kill quiescent pancreatic cancer cells but not normal quiescent cells 34 . Thus, DYRK1A and DYRK1B may be markers of dormant cells and testing the expression and function of these proteins in DTCs may identify a role for quiescence in residual disease.
Pausing proliferation to repair damage is a stress response conserved across evolution 40 . Farnesyl transferase inhibitors (FTIs) can induce a growth arrest in breast cancer cells for about 15 days in vitro. Cells that entered this arrest established a RHOC hi /RHOA low signalling ratio that activated the stress-activated kinase JUN N-terminal kinase (JNK) that was required for the growth arrest 41 . Similarly, upstream kinases such as MKK4 (also known as MAPKK4) that can also activate JNKs can induce dormancy in other systems 42, 43 . This supports the hypothesis that the activation of stress signalling pathways 11, 18, [44] [45] [46] could induce a sustained state of quiescence linked to dormancy.
The integration of differentiation and stress pathways has been shown to regulate dormancy, but these pathways may have cell type-specific effects. This is particularly relevant . The time required for premalignant or undectable lesions is unknown and is indicated in the figure as 'Years?'. In fact, at the time of diagnosis, tumour cell dissemination has occurred in >50% of patients 1, 9 . After primary tumour surgery and/or treatment (indicated by arrows), the tumour mass decreases and residual disease characterized by solitary dormant DTCs can be detectable for long periods (dashed blue line). After months, years or decades the metastatic tumour mass then increases (dashed red lines and tumour cell clusters). DTCs that originate from different stages of tumour evolution could form these heterogeneous masses 1, 9 . For example, late DTCs, which arise from the established primary tumour may have higher metastatic potential and give rise to metastatic lesions earlier (within months of ending treatment of the primary tumour). By contrast, early DTCs (light blue) from pre-invasive lesions that remain dormant may generate metastatic tumours decades after first diagnosis. These DTCs may be the first colonizers of distant organs but may have remained in a dormant state while the primary tumour progressed. As the primary lesions progress, additional DTCs reach the target organs and contribute to dormant and proliferative DTC heterogeneity 65, 66 . b | A hypothetical possibility discussed in BOX 1 is that early DTCs may, by colonizing target organs, become the founders of early DTC pre-metastatic niches (EDPNs) by crosstalk (arrows) with different host cell types such as endothelial cells, immune cells, fibroblasts and/or other stromal cells. EDPNs could support the dormancy and/or outgrowth of later arriving DTCs from later stages of evolution. Note that in part b, the same process can proceed for early DTCs that go on to form metastases independently of late DTCs (blue tumour mass in part a).
Unfolded protein response (UPR).
A cellular response to stress unique to the endoplasmic reticulum (ER) that senses the misfolding of proteins in the ER caused, for example, by overloading of the ER, oxidative damage or protein unfolding during synthesis. It activates a series of pathways that will help cells to survive by correcting the proteotoxicity caused by unfolded proteins or by activating mechanisms of cell death.
in leukaemias as opposed to carcinomas. For example, in normal T cells, in contrast to epithelial cells, enhanced p38 activation can block T cell differentiation and induce growth arrest of immature thymocytes 47 , whereas ERK1 and ERK2 activation favours T cell differentiation 47 . In T cell acute lymphoblastic leukaemia (T-ALL), ERK1, ERK2 and p38 are inactivated by the ERK and p38 phosphatase MKP1 (also known as DUSP1) 48 . In dormant T-ALL cells, MKP1 is downregulated 48 . MKP1 in turn can be upregulated by NOTCH3, and this upregulation has been shown to induce dormancy escape in T-ALL cells in vivo. These data argue that during T-ALL dormancy maintaining high activation of both ERK and p38 signals simultaneously keeps these cells quiescent but uncommitted to full differentiation.
Activation of p38 and/or the unfolded protein response (UPR), an adaptive ER stress tolerance mechanism 49 , might promote the survival of dormant tumour cells 50 . A proteomic analysis revealed that p38-induced dormancy resulted in a UPR. Induction of protein disulphide isomerase (PDI) and GRP78 (also known as BiP) in dormant cells due to p38 activation resulted in the survival of these cells when exposed to chemotherapy and/or nutrient deprivation via BAX inhibition 50 , possibly through BIK upregulation 51 . This survival response was concomitant with ATF6α activation, an inducer of GRP78 (REF. 17 ). Proteomic analysis of bone marrow DTC cell lines obtained from patients with breast, prostate or lung cancer, revealed the upregulation of PDI, GRP78 and GRP94 (REFS 52, 53) . This may be due to hypoxia 54 found in the bone marrow microenvironment 55 , which is known to induce a UPR owing to low nutrient and ATP availability 56, 57 . Interestingly, expression of GRP78 and GRP94 was increased in DTCs isolated from bone marrow aspirates from patients with breast cancer 52 and, clinically, GRP78 upregulation in primary breast cancer correlates with a poor prognosis 58 . Cytokeratin 19 (CK19) upregulation also coordinated a UPR to promote the survival and the growth arrest of breast carcinoma cells by activating p38 and XBP1 (a UPR-regulated transcription factor), which in turn induce the PDI-like protein ERP29 (REF. 59 ). The above studies suggest that the activation of stress signalling might explain how DTCs survive therapy-induced or microenvironment-induced stress in different cancer types.
Microenvironmental regulation of dormancy
DTCs that survived dissemination and a new tissue microenvironment seem to undergo a default dormancy response before reactivation [60] [61] [62] . The ability of different organs to support DTC growth has led to the classification of microenvironments as dormancy-permissive or dormancy-restrictive 18, 63, 64 . This distinction is clinically relevant because in many cancer types DTC incidence in various organs is much higher than metastasis incidence in those organs, suggesting that the microenvironment influences DTC fate 4 . For example, the incidence of bone marrow DTCs is high in patients with gastric cancer, but clinically the incidence of bone metastasis is rare and bone marrow DTCs are commonly negative for proliferative markers, suggesting that they survive in a non-proliferative state 1, 4, 7, 65, 66 . Mouse models of other tumour types concur with these data, as DTCs are found in animals with pre-malignant mouse mammary tumour virus (MMTV)-ERBB2 (also known as HER2)-positive lesions that are considered non-invasive 66 (FIG. 1) . The number of ERBB2 + DTCs was never found to be higher than 10 4 per bone marrow sample and bone metastasis did not develop in any cases. However, when DTCs were transplanted from MMTV-ERBB2 mice into lethally irradiated wild-type siblings, ERBB2 + bone marrow transplant recipients developed bone marrow carcinosis; this was not observed in non-irradiated recipient mice 66 . These data suggest that signals encoded in specific microenvironments dictate DTC fate.
Dormancy-permissive microenvironments.
The signals that regulate haematopoietic stem cell (HSC) dormancy in the bone marrow, including growth arrest-specific protein 6 (GAS6), bone morphogenetic protein 4 (BMP4), BMP7 and transforming growth factor-β2 (TGFβ2), could induce residual disease dormancy in different types of cancer 18,67-72 (FIGS 2,3). GAS6, which is a stromal-derived ligand of the MER, TYRO3 and AXL (also known as UFO) tyrosine kinase receptors, regulates HSC survival 73 . Leukaemia cells with the E2A-PBX1 fusion protein express high levels of MER 67 , and when these cells are in contact with human osteoblasts, which produce GAS6 (FIG. 2) , they enter a G0/G1 arrest and are protected from chemotherapy-induced apoptosis 67 . Similar studies with prostate cancer cell lines showed that GAS6 induces prostate cancer DTC dormancy but only when AXL receptor signalling predominates. This evidence supports the idea that HSC niche signals could induce dormancy [68] [69] [70] 74 . Along the same lines, BMP7, a TGFβ family member secreted by normal bone marrow stromal cells, induced ERK inhibition and p38 activation (a low ERK/p38 signalling ratio) 75, 76 and dormancy of prostate DTCs (PC3 and other human prostate cancer cell lines) injected into the bone 71 . This was dependent on the induction of the Box 2 | Dormancy: cell cycle arrest due to reduced mitogenesis?
Is dormancy simply growth arrest due to a lack of mitogenic signalling? Growth arrest due to senescence, a replicative arrest that is triggered by signals such as oncogene-induced stress 142 , does not emerge as a central mechanism in cellular dormancy studies. As senescence is an irreversible barrier to transformation, this suggests tumour cells would not re-activate the senescence programme to become dormant [143] [144] [145] .The fact that disseminated tumour cells (DTCs) are found in a non-proliferative or possibly a slow-cycling phase suggests that G0/G1 arrest will be an inescapable part of this biology. However, a dormancy signature that predicts late relapse in breast cancer, for example 44, 111 , seems to contain genes other than those differentially regulated in cells deprived of growth factors 146 . These differentially regulated genes include those involved in regulating the quiescence of normal stem cells 44, 131 . For example, ~62% of the genes induced in quiescent normal muscle, hair follicle and haematopoietic stem cells 131 are upregulated in dormant head and neck squamous cell carcinoma cells 44 . Signals in normal stem cell niches seem to regulate dormancy 71, 147 , and these same cues repress oncogene signalling via quiescence induction 120 . Perhaps dormancy of DTCs may be an active programme that recapitulates quiescence of normal stem cells. However, in dormant DTCs cell cycle arrest is coupled to a persistent but latent form of tumour-initiating or pluripotent capacity that provides an adaptive and survival advantage that eventually fuels tumour growth.
metastasis suppressor protein NDRG1 and the CDK inhibitor p21 (REF. 71 ). Knockdown of the BMP7 receptor BMPR2 inhibited BMP7-induced DTC dormancy 71 and an inverse correlation between BMPR2 expression and bone metastasis was found in patients with prostate cancer 71 . Thus, loss of BMPR2 may allow DTCs to escape dormancy. NDRG1 also suppresses metastasis in prostate cancer and breast cancer models by binding to LRP6 and blocking WNT-induced metastasis 77 . Similarly to BMP7, BMP4 is another BMPR2 ligand, and inhibition of BMP4 by the secreted antagonist COCO (also known as DAND5) induces the proliferation of dormant mouse mammary 4T07 DTCs in the lungs, a tissue with abundant BMP4 (REF. 72 ). However, in this model NDRG1 had an opposing function and was linked to COCO-induced metastasis. It is possible that NDRG1 functions differently in mouse versus human epithelial cancer cells or in different organs.
A third signal that regulates HSCs and induces dormancy of HNSCC DTCs in the bone marrow is TGFβ2 (REF. 18 ). TGFβ2 induced a low ERK/p38 signalling ratio, which induced the metastasis suppressor DEC2 (also known as SHARP1 and BHLHE41) 18 . In turn, DEC2 repressed CDK4 and induced p27 to induce bone marrow DTC quiescence. Importantly, inhibition of p38 or TGFβR1 (a TGFβ2 receptor) induced HNSCC multiorgan (liver, spleen, bone marrow and lung) proliferation of DTCs in mice 18 . In mouse lung, host-derived TGFβ2 was less abundant than in the bone marrow, providing clues for the organ-specific 'seed and soil' mechanisms 78 (FIG. 2) . Other studies showed that inhibiting the lysophosphatidic acid receptor (EDG2; also known as LPAR1) in breast cancer DTCs also caused dormancy owing to the induction of a low ERK/p38 signalling ratio 79 . These studies provide a new molecular description of how signals that control normal tissue function or the inhibition of signals that stimulate reactivation may enforce a dormancy phenotype in solitary DTCs lodged in those niches (FIGS 2,3) . Dormancy-restrictive microenvironments. The switch that regulates escape from dormancy has also been studied. For example, upregulation and activation of the adhesion protein vascular cell adhesion protein 1 (VCAM1) induced escape from dormancy in metastatic breast cancer cell lines that were dormant in mouse bone marrow 19 (FIGS 2,3 ). In this model, these bone marrow VCAM1
hi DTCs bound to α4β1 integrin expressed by osteoclasts 19 and recruited osteoclast progenitors, which together resulted in bone metastases 19 . However, the mechanisms underlying VCAM1 silencing and re-expression in these bone marrow DTCs are unknown. Another study has shown that dormancy escape 80 is promoted by periostin (POSTN), which is produced by fibroblasts 81 or endothelial tip cells that surround single dormant DTCs (FIGS 2,3) .
DTCs can also remodel their microenvironment to support proliferation after dormancy exit. Green et al.
showed that the inhibition of myosin light chain kinase (MLCK) induced the dormancy of solitary DTCs in the lung, thus reducing the number of breast cancer lung macro-metastases 82 (FIGS 2,3) . Thus, MLCK regulates a dormancy-to-proliferation switch. Furthermore, using in vitro three-dimensional (3D) modelling they showed that production of fibronectin and β1 integrin activated MLCK and stress fibre formation to maintain proliferation 82 . Others 83 reproduced the first studies 84, 85 showing that FAK, SRC and β1 integrins are required to prevent dormancy onset 46, 86 . Importantly, pharmacological inhibition of SRC alone induced the dormancy or slow cycling of breast cancer cells, while inhibition of both MEK1 and SRC caused apoptosis of DTCs 46 , suggesting that this pathway can be specifically targeted in DTCs in different niches (FIG. 2) .
That the cytoskeletal architecture can signal to reactivate dormant tumour cells suggests that ECM stiffness might promote dormancy escape (FIGS 2,3) . In hepatocellular carcinoma cells (HCCs), increased matrix stiffness was linked to increased TGFβ1 signalling, induction of cyclin D1 and cyclin D3, and proliferation in vitro 87 . Thus, microenvironments that are less rigid might support DTC quiescence. Although this hypothesis awaits in vivo validation, it was shown in a breast cancer model that TGFβ1-induced fibrotic lungs (that are associated with type I collagen deposition) could support dormancy escape 88 . . An example of this may be tumour cells that are known as drug-tolerant persisters that survive targeted therapies by altering epigenetic mechanisms 149 . These drug-tolerant residual tumour cells could be compared with disseminated tumour cells (DTCs) from patients in remission to determine mechanisms that are common to both.
Another frequent question is whether 'awakening' dormant tumour cells may facilitate their eradication with conventional anti-proliferative therapies. However, the clinical evidence suggests that chemotherapy treatment of highly proliferative local and distant lesions does not always fully stop their progression. In addition, residual DTCs are genetically heterogeneous 9, 65, 66, 133, 150 and awakening dormant DTCs would expand the genetic, and probably epigenetic, repertoire of mechanisms that would allow systemic disease to resist therapy. In support of this, awakened dormant tumour cells seem to rapidly fuel tumour recurrence in experimental systems 18, 46, 151 . Thus, we argue against awakening dormant DTCs and instead support keeping them dormant or eradicating them while dormant as an alternative strategy. Endothelial cell
Cytotoxic immune cells from the T cell lineage that are specialized in killing target cells (that is, virus-infected cells).
Angiogenesis
The formation of new blood vessels that create new pathways for blood flow during normal tissue development or remodelling or during pathological conditions such as tumour growth or retinopathy.
why dormancy is such a stable phenotype (FIG. 2) . The reviewed data support the general principle that solitary cell dormancy can be traced back to the reciprocal crosstalk between cells and their niches and the regulation of mitogenic and stress signalling pathways (FIGS 2,3).
Immune modulation of tumour dormancy
The above data focused on ECM or soluble ligands as cues within the microenvironment. However, the immune cells are a key component of the microenvironment 89, 90 (FIG. 2) . The immune system is a default constituent of the tumour microenvironment having both pro-tumour and antitumour functions 90 . Recipients of organs from donors who were disease-free but who had previously had melanoma develop melanoma metastasis in the transplanted organ after immunosuppression, suggesting that dormant cells were kept in check by the immune system 91 . However, it is unclear whether DTC reactivation is immune system-dependent or whether it is due to other microenvironmental changes from transplantation. There are few studies with clinically relevant models that have examined this. One example is of dissemination in uveal melanoma in RET.AAD mice that constitutively express the RET oncogene in melanocytes and thus develop spontaneous uveal melanoma 92 . DTCs in these mice were found in almost all organs, including the lungs, reproductive tract and skin, as early as 2 weeks after primary tumours appeared 92 . Maintenance of dormancy in the DTCs in the lung and reproductive tract required CD8 + T cells, as mice depleted of these cells with antibodies developed metastasis with a much shorter latency than those with CD8 + cells (FIG. 2) . Interestingly, cutaneous metastases grew despite CD8 + T cell depletion, suggesting an organ-specific function for CD8 + T cells and DTC fate. However, whether CD8 + T cells kill or induce the growth arrest of single DTCs remains unclear (FIG. 2) . This is important because there is no direct clinical proof that the immune system is involved in the growth arrest of non-proliferative solitary DTCs or in controlling their numbers via immune editing. Tumour mass dormancy might also depend on adaptive immunity. In immunogenic 3ʹ-methylcholantreneinduced sarcoma models, around 80% of small stable tumour masses remained static for >150 days before spontaneous regression to undetectable levels. The static tumours had a high apoptotic fraction and a low Ki67 index (a marker of G0 exit), which was consistent with CD8 + T cell-mediated cytotoxicity and cytostasis. However, the small tumours resumed growth after CD8 + and CD4 + T cell depletion 93 (FIG. 2) .
T cell-induced tumour mass dormancy may also involve crosstalk with endothelial cells and angiogenesis inhibition. In the pancreatic RIP-Tag2 cancer mouse model, pre-malignant adenomas develop by week 6-8 and adenocarcinomas by week 10 (REF. 94 ), and injection of CD4 + T cells at week 7-8 arrested tumour progression independently of CD8 + T cells via tumour necrosis factor . In addition, this environment may also lack proliferation reactivation signals such as type I collagen-dense microenvironments 88 , fibronectin 153 , COCO or TGFβ3 ligand 147 . b | The immune niche contains macrophages, CD4
+ cells or CD8 + cells that may produce interferon-γ (IFNγ), which may induce dormancy in tumour cells 93, 94 . In particular, tumour necrosis factor receptor 1-positive (TNFR1 
Angiogenic switch
Occurs when a small tumour mass senses the lack of appropriate blood supply and activates a series of transcriptional programmes that allows the production of signals that will recruit new blood vessels.
receptor 1 (TNFR1) and interferon-γ (IFNγ) signalling 94 (FIG. 2) . CD4 + T cell-mediated antitumour effects were due to the release of the potent angio genesis inhibitors CXCL9 and CXCL10 and to reduced ανβ3 integrin expression 94 . A similar function for CD4 + T cells but not CD8 + T cells was observed with a vaccination protocol that targeted tumour blood vessels 95 . Finally, IFNγ derived from T helper 1 cells can induce tumour cell senescence in a T antigen-induced pancreatic cancer model that is irreversible, unlike quiescence 96 . These studies show that these immune-mediated microenvironmental responses can induce marked growth arrest phenotypes 96 (FIG. 2) . Interestingly, they seem to converge on IFNγ signalling as a powerful inducer of a growth arrest and potentially a dormancy-inducing signal (FIG. 2) . Although these studies did not address residual disease dormancy, they may provide mechanistic information to model the regulation of solitary DTC fate, the stage at which the immune system might have a better chance to curtail metastasis development.
The above data suggest that further work is necessary to conclusively determine whether the effects of CD4 + and CD8 + T cells on DTC behaviour require active cytotoxicity or whether they are the result of the immune system creating a microenvironment non-permissive for tumour expansion.
Cellular dormancy and angiogenic dormancy
Like normal tissues, tumours require a functional vasculature. When a DTC grows into a micrometastasis it recruits a new vasculature. If angiogenesis fails, cell death proceeds and equilibrium between proliferation and apoptosis can keep a small tumour mass constant and clinically dormant 97 . This could persist until genetic, epigenetic or microenvironmental signals trigger the angiogenic switch. However, there is no evidence to support the persistence of angiogenic dormancy for years or decades in patients. A study of angiogenic-poor dormant tumour masses 98 in in vivo models of breast cancer, gliobastoma, osteosarcoma and liposarcoma that remain dormant . Proliferative DTCs also require activation of growth factor signalling via ERBB family receptors such as epidermal growth factor receptor (EGFR), which can be coupled to uPAR and β1 integrin signalling that can be activated by extracellular matrix (ECM) molecules such as fibrillar fibronectin (fFN) via α5β1 integrins or by heterotypic interaction with vascular cell adhesion protein 1 (VCAM1) 153 . Receptor tyrosine kinases like the ERBB family funnel proliferative signals through FAK, SRC and the MEK-ERK modules to cyclin D1 and cyclin D3 or through myosin light chain kinase (MLCK). Other growth-promoting pathways activated in proliferative DTCs include the canonical transforming growth factor-β1 (TGFβ1) signalling pathway. Signals between the EGFR and TGFβ signalling pathways are integrated through as yet unknown mechanisms. b | In dormant DTCs TGFβ2 and bone morphogenetic protein 4 (BMP4) or BMP7 signals predominate, activating p38, inhibiting ERK1 or ERK2 (for example, by TGFβ2, BMP7 or EDG2 inhibition), and inducing p21 and p27 cyclin-dependent kinase (CDK) inhibitors (in all cases) 18 . Specific TGFβ2 canonical (SMAD1 or SMAD5) and non-canonical signalling result in the upregulation of DEC2 and BMP7 signalling 71 and induce NDRG1 that subsequently leads to the induction of cell cycle inhibitors and prostate cancer cell dormancy. Paradoxically, in mouse mammary cancer models NDRG1 was also shown to be induced by COCO 147 and to support metastasis. Importantly, dormant DTCs may also be sensitive to the growth arrest-specific protein 6 (GAS6) 109 or become unable to derive proliferative signals from fibronectin in the ECM through α5β1 integrins (previously reviewed in REF. 4 ). Question marks indicate unknown mechanisms or factors.
in immunodeficient mice for >90 days 99 showed that thrombo spondin (TSP) and angiomotin were upregulated in these tumours, although their functional relevance was unclear. Recently, Ghajar et al. 80 found that breast cancer DTCs reside in a dormant state on the microvasculature in organs to which they have metastasized. Using in vitro 3D tissue modelling they found that endothelial cells in the stable microvasculature produce TSP, which keeps solitary DTCs in a dormant state. This effect of the endothelium on the tumour cells may at least partly explain the previously reported effect of TSP on the dormancy of small tumour masses that show low vascular densitiy 100, 101 . By contrast, in sprouting neovasculature, the tip cells produce TGFβ1 and POSTN, which may allow the solitary tumour cells to initiate proliferation 80 (FIG. 2) . This suggests that angiogenesis regulators such as TSP that control a vascular switch triggered by poor oxygenation might also regulate solitary DTC behaviour (cellular dormancy (FIG. 2) ). This suggests that molecules such as TSP might influence DTC activity and that tumour angiogenesis is the consequence of DTCs switching from dormancy to proliferation. Additional work could determine how TSP and POSTN regulate solitary DTC quiescence versus tumour mass dormancy and whether tumour mass dormancy is indeed occurring in patients.
Overexpression of the Notch signalling ligand deltalike 4 (DLL4) in endothelial cells can promote T-ALL cells to exit dormancy by binding to the NOTCH3 receptor on T-ALL cells 102 (FIG. 2) . Furthermore, this overexpression of DLL4 can be induced by vascular endothelial growth factor (VEGF) 102 . Thus, modulating the endothelial cell and dormant DTC interactions by using, for example, VEGF inhibitors, may be a new avenue to prevent dormancy exit.
To further study how endothelial cells might drive tumour cell entry and exit from dormancy, one study showed that expression of the angiogenesis inducers epoxyeicosatrienoic acids (EETs) in the endothelium 103 stimulated exit from tumour mass dormancy in mice 99 . EETs stimulated metastasis of various xenograft tumours, including Lewis lung carcinomas and B16-F10 melanomas 103 . These studies suggest that endothelial cell-DTC interactions might substantially predate any micrometastasis that arises and remains dormant because of a reduced vasculature 104 (FIG. 2) . In addition to endothelial cells, other cell types may also foster a switch from dormancy, for example, recruitment of vascular (CD105 + ) and myeloid (CD11b + and F4/80 + ) cells by tissue factor signalling can interrupt the dormancy of glioma cells in vivo 98, 105 (FIG. 2) .
We propose that before angiogenic dormancy, which may be short-lived on the basis of mathematical modelling of human cancer kinetics 106, 107 , endothelial cells might establish niches that support cellular dormancy. Accordingly, live in situ imaging of melanoma and breast cancer DTCs in the mouse brain showed that these cells survive by establishing strict perivascular localization and direct contact with endothelial cells 108 . These DTCs remained dormant even though they are directly attached to endothelial cells in blood vessels (also observed in REF. 80) (FIG. 2) . Findings such as these challenge the angiogenic dormancy theory that proposes that decreased oxygenation is the dominant driver of tumour cell dormancy. Thus, targeting the survival niche of solitary DTCs might be a more efficient strategy to stop metastatic growth.
Targeting dormancy
Recent studies have identified cues that induce dormancy 18,44,71,72,109 and specific organs that are restrictive sites for metastasis due to dormancy induction 18, 67 . This knowledge could help to develop therapies (BOX 3) that mimic the dormancy programme to sustain, rather than awaken, dormant DTCs and thereby prevent relapse.
Drugs already in the clinic may be useful to induce dormancy in DTCs
. One study showed that, in both primary cells and breast cancer and leukaemia cell lines, the DNA methylation inhibitor 5-azacytidine alone caused decreased expression of G0 to G1 exit genes -such as DNMT1 and FOXM1 -that are also downregulated in haematological and epithelial tumour dormancy models 44, 110 . Remarkably, expression of other key genes upregulated in the p38-induced dormancy signature 44, 111 , such as RARB and CDKN1A, were induced by 5-azacytidine 110 . Thus, demethylating agents coupled to specific RARα and RARβ agonists could be used to reprogramme tumour cells into dormancy
. In fact, our unpublished work indicates that a combination of all-trans retinoic acid and 5-azacytidine recapitulates the hallmarks of dormancy in vivo identified in bone marrow and p38-induced dormancy 18, 44, 111 and induces a prolonged and stable quiescence.
Uveal melanoma is another type of cancer in which epigenetic mechanisms might be manipulated for dormancy induction with currently available drugs. For example, inactivating mutations in BAP1 (REF. 112) promote epigenetic deregulation, leading to poorly differentiated metastatic tumours that resemble primitive neuroectoderm. Histone deacetylase (HDAC) inhibitors, such as LBH-589, converted uveal melanoma lines from class 2 (high metastatic risk) to class 1 (low metastatic risk) 113 and induced a G0/G1 arrest and epigenetic reprogramming consistent with melanocytic differentiation. Thus, HDAC inhibitors or DNA demethylating agents might represent alternative adjuvant therapies to induce prolonged dormancy of uveal melanoma or other types of DTCs
.
Future directions
The work reviewed here reveals an apparent 'fine-tuning' of cancer dormancy research into specific areas. An emerging theme includes how the interaction of endothelial cells with DTCs affects their dormancy (FIG. 2) . Analysis of dormancy-inducing cues identified BMP4, BMP7 and TGFβ2, among others 18, 71, 72, 109 . These are ligands involved in regulating normal stem cell biology [114] [115] [116] [117] . This identifies another emerging theme in which dormant tumour cells might recapitulate evolutionary conserved programmes of normal stem cell quiescence, coordinating growth arrest and pluripotency for prolonged periods 118, 119 120 . Dormancy may require robust epigenetic programming. Although much is unknown about the epigenetics of DTCs there is sufficient expertise in other areas of biology that could be applied to DTCs [121] [122] [123] , such as the mechanisms underlying stem cell plasticity and EMT [124] [125] [126] [127] . For example, p38 limits self-renewal 128 , which is a property of stem cells, and a p38-regulated dormancy gene signature was associated with longer metastasis-free periods in patients with oestrogen receptor-positive breast cancer 44, 111 . In addition, several genes in this p38-regulated dormancy signature are epigenetic regulators such as NR2F1, TGFB2 and DNMT1 (REFS 121, 129, 130) , Specifically, TGFβ2 and NR2F1 can limit induced pluripotent stem cell (iPSC) reprogramming via the regulation of chromatin remodelling 121 , and NR2F1 is associated with a dormant pheno type that is characterized by repressive chromatin 127 (M.M.S., P.B. and J.A.A.-G., unpublished observations). These similarities between dormant tumour cells and adult stem cells, might assist in determining which epigenetic mechanisms regulate the long-term commitment of DTCs to quiescence while retaining growth potential 115, 131 
Box 4 | DTC and niche markers that may dictate DTC targeting
Patients with disseminated tumour cell (DTC)-negative bone marrow commonly have a favourable outcome and could be monitored for DTC appearance 63 . However, bone marrow aspirates positive for DTCs (at the time of surgery or after treatment) are considered to be indicative of a poor prognosis. In this group, DTCs from different types of cancer (see the table) could be profiled for markers that indicate whether DTCs are proliferating (such as increased expression of COCO, fibronectin, periostin (POSTN), transforming growth factor-β1 (TGFβ1) or phosphorylated ERK (P-ERK) and low expression of phosphorylated p38 (P-p38)) or dormant (such as low expression of P-ERK, high expression of P-p38, TGFBR3, bone morphogenetic protein receptor type 2 (BMPR2), TGFβ2 or BMPs) 63 . If proliferative markers are found then DTCs could be targeted with conventional anti-proliferative treatments in combination with a dormancy-inducing therapy. If DTCs displayed dormancy markers then drugs to induce dormancy could be used to prolong dormancy. Markers or expression profiles from DTCs might help to identify specific targets in the unfolded protein response (UPR) and chaperone pathways that, when blocked, could eradicate DTCs. This could be followed by dormancy-inducing or dormancy-maintaining treatments. DTCs positive for interferon-γ (IFNγ) receptors may be sensitive to immune therapy that affect DTCs via cytostatic and cytotoxic mechanisms or via the regulation of vascular niches. Specific examples are provided in the table for A question linked to early dissemination (BOX 1; FIG. 1) , is whether the genetic alterations that are present in early DTCs might predispose these cells to dormancy. Perhaps a subpopulation of DTCs that evade therapy and evolve in parallel to the primary tumour could result in delayed relapse, as evolution in distant organs may follow different kinetics. DTCs in patients with breast cancer without distant metastasis carry specific chromosomal gains such as 5cen-5q23.3 or 18q 132, 133 . Could some of these gains induce DTC dormancy? NR2F1, a gene that is induced in dormancy models, and that is known to induce quiescence and lineage commitment, is located in the 5q region and was independently found to be linked to a locus that limits progression in breast cancer 134 . Perhaps DTCs overexpressing NR2F1 may remain dormant until additional genetic and/or epigenetic changes override this signal.
The current research provides insight into the complexities of cancer dormancy but also into the opportunities that might come from understanding this process. To apply this knowledge, clinicians will need markers informative of the dormancy status of DTCs 63
. Concomitantly, drug development must focus on targeting these cells, because markers without a therapeutic option will be of limited benefit 63 . Finally, proper clinical trials to test dormancy therapies are essential. As recently explained 135, 136 , clinical trials that use the time to first metastasis and the time to next metastasis as clinical parameters may help to determine whether new drugs are affecting dormant DTCs or whether they are inducing dormancy of proliferative DTCs. Importantly, not all cancers may be clinically dormant after diagnosis and treatment as some, like triple-negative breast cancer or pancreatic cancer, can recur as early as 3 years after ending treatment. However, the timing of recurrence is tied to the time of diagnosis. Early recurrence does not negate the fact that the metastases may have initiated from DTCs, such as early DTCs that persisted in a dormant state for a long time and gave rise to metastasis only a few years after diagnosis.
Minimal residual disease represents a new and challenging area of cancer biology that awaits exploration. The detection of DTCs in patients has been strongly suggested to be a risk factor for metastasis [137] [138] [139] . However, the enumeration and risk analysis will only be able to be addressed when this information is linked to detailed mechanistic analysis of DTC biology. The data summarized in this Review show that the field is moving promisingly in that direction.
Although not yet considered a 'hallmark' of cancer 140 , in many cancer types tumour cell dormancy may be a rite of passage for cancer relapse. Understanding cancer dormancy will answer longstanding questions regarding how to treat the most lifethreatening hallmark of cancer 140 
